JP2020509767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509767A5 JP2020509767A5 JP2019550622A JP2019550622A JP2020509767A5 JP 2020509767 A5 JP2020509767 A5 JP 2020509767A5 JP 2019550622 A JP2019550622 A JP 2019550622A JP 2019550622 A JP2019550622 A JP 2019550622A JP 2020509767 A5 JP2020509767 A5 JP 2020509767A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- amino acid
- cdr2
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471956P | 2017-03-15 | 2017-03-15 | |
| US62/471,956 | 2017-03-15 | ||
| PCT/US2018/022759 WO2018170338A2 (en) | 2017-03-15 | 2018-03-15 | High affinity mage-a1-specific tcrs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021039957A Division JP2021090462A (ja) | 2017-03-15 | 2021-03-12 | 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509767A JP2020509767A (ja) | 2020-04-02 |
| JP2020509767A5 true JP2020509767A5 (enExample) | 2021-04-22 |
| JP7037577B2 JP7037577B2 (ja) | 2022-03-16 |
Family
ID=63523985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550622A Expired - Fee Related JP7037577B2 (ja) | 2017-03-15 | 2018-03-15 | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| JP2021039957A Pending JP2021090462A (ja) | 2017-03-15 | 2021-03-12 | 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021039957A Pending JP2021090462A (ja) | 2017-03-15 | 2021-03-12 | 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11034748B2 (enExample) |
| EP (1) | EP3595708A4 (enExample) |
| JP (2) | JP7037577B2 (enExample) |
| KR (1) | KR102375033B1 (enExample) |
| CN (1) | CN110582299A (enExample) |
| AU (1) | AU2018234830B2 (enExample) |
| BR (1) | BR112019018863A8 (enExample) |
| CA (1) | CA3055983A1 (enExample) |
| EA (1) | EA201992131A1 (enExample) |
| IL (1) | IL269250A (enExample) |
| MX (1) | MX2019010972A (enExample) |
| SG (1) | SG11201908527SA (enExample) |
| WO (1) | WO2018170338A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102523449B1 (ko) | 2016-04-08 | 2023-04-19 | 어댑티뮨 리미티드 | T 세포 수용체 |
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| RS62865B1 (sr) | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Novi t-ćelijski receptori i imunoterapija u kojoj se koriste |
| EP3595708A4 (en) * | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES |
| SG11202010262TA (en) | 2018-04-19 | 2020-11-27 | Baylor College Medicine | Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| TWI850360B (zh) | 2019-04-04 | 2024-08-01 | 德商梅迪基因免疫治療公司 | 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途 |
| MX2021013218A (es) | 2019-05-01 | 2021-12-10 | Pact Pharma Inc | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| JP2023513350A (ja) * | 2020-02-14 | 2023-03-30 | アダプティミューン・リミテッド | がんまたは腫瘍の治療の方法 |
| CN111320703A (zh) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | 靶向cd22的嵌合抗原受体及其应用 |
| CN111499763A (zh) * | 2020-03-31 | 2020-08-07 | 江苏省省级机关医院 | 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用 |
| CA3178588A1 (en) * | 2020-05-13 | 2021-11-18 | Mark Edward DUDLEY | Method of treatment of cancer or tumour |
| CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
| TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| US20240197877A1 (en) * | 2021-04-14 | 2024-06-20 | Tscan Therapeutics, Inc. | Binding proteins recognizing ha-2 antigen and uses thereof |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954B2 (en) | 2021-10-29 | 2026-04-23 | Gilead Sciences, Inc. | Cd73 compounds |
| US20230310607A1 (en) | 2021-11-09 | 2023-10-05 | T-Knife Gmbh | Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| CN116063457A (zh) * | 2022-04-27 | 2023-05-05 | 恒瑞源正(广州)生物科技有限公司 | Mage-a1特异性t细胞受体及其用途 |
| CN119317638A (zh) * | 2022-06-01 | 2025-01-14 | 北京可瑞生物科技有限公司 | Mage-a1特异性tcr及其用途 |
| NL2032130B1 (en) | 2022-06-10 | 2023-12-18 | Academisch Ziekenhuis Leiden | T cell receptors directed against melanoma-associated antigen and uses thereof |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025146286A1 (en) * | 2024-01-04 | 2025-07-10 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026089992A1 (en) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596536B1 (en) * | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| AU2003215869B2 (en) | 2002-03-15 | 2008-04-24 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| AU2004208031B2 (en) | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| GB0511124D0 (en) * | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| EP2650366B1 (en) | 2005-10-18 | 2017-03-22 | Precision Biosciences | Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity |
| US20080064631A1 (en) * | 2006-01-13 | 2008-03-13 | Jeffrey Molldrem | T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease |
| US8871211B2 (en) * | 2006-09-28 | 2014-10-28 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| US10093977B2 (en) * | 2007-03-05 | 2018-10-09 | International Institute Of Cancer Immunology, Inc. | Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them |
| KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| WO2010088160A1 (en) * | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US9228007B1 (en) * | 2010-03-11 | 2016-01-05 | The Regents Of The University Of California | Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells |
| EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
| AU2011304728A1 (en) * | 2010-09-20 | 2013-03-14 | Biontech Ag | Antigen-specific T cell receptors and T cell epitopes |
| WO2012054825A1 (en) | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| KR20140039318A (ko) * | 2011-06-28 | 2014-04-01 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자 |
| WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| CN102295702B (zh) * | 2011-08-26 | 2014-01-29 | 中国科学院微生物研究所 | 一种针对t细胞受体可变区特异性单抗的制备方法 |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| PL3824905T3 (pl) | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2896697B1 (en) | 2012-12-12 | 2015-09-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| JP2016509582A (ja) | 2012-12-19 | 2016-03-31 | アンプリミューン， インコーポレイテッド | 抗ヒトｂ７−ｈ４抗体およびその使用 |
| HUE050390T2 (hu) * | 2013-01-29 | 2020-11-30 | Max Delbrueck Centrum Fuer Molekulare Medizin Mdc | MAGE-A 1-t felismerõ nagy aviditású kötõ molekulák |
| EP2971045B1 (en) * | 2013-03-13 | 2019-06-19 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
| WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| EP3071594A4 (en) * | 2013-11-22 | 2017-05-03 | The Board of Trustees of the University of Illionis | Engineered high-affinity human t cell receptors |
| SI3708579T1 (sl) * | 2014-04-01 | 2024-09-30 | Biontech Cell & Gene Therapies Gmbh | Klavdin-6 specifični imunoreceptorji in T celični epitopi |
| US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
| EP2944652A1 (en) * | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
| CA2956545A1 (en) * | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| CN113698488A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| EP3193892A4 (en) * | 2014-09-14 | 2018-09-12 | Washington University | Personalized cancer vaccines and methods therefor |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| CN106188274A (zh) * | 2015-05-06 | 2016-12-07 | 广州市香雪制药股份有限公司 | 识别rhamm抗原短肽的t细胞受体 |
| NZ737400A (en) * | 2015-06-01 | 2019-09-27 | Medigene Immunotherapies Gmbh | T cell receptor library |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| CN105316362B (zh) * | 2015-08-19 | 2020-03-17 | 暨南大学 | 一种Dual-RMCE介导的TCR基因置换系统及其方法 |
| CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
| EP3472208B9 (en) * | 2016-06-17 | 2023-10-04 | Medigene Immunotherapies GmbH | T cell receptors and uses thereof |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| EP3595708A4 (en) * | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES |
-
2018
- 2018-03-15 EP EP18767104.5A patent/EP3595708A4/en not_active Withdrawn
- 2018-03-15 CA CA3055983A patent/CA3055983A1/en active Pending
- 2018-03-15 WO PCT/US2018/022759 patent/WO2018170338A2/en not_active Ceased
- 2018-03-15 KR KR1020197029977A patent/KR102375033B1/ko not_active Expired - Fee Related
- 2018-03-15 AU AU2018234830A patent/AU2018234830B2/en not_active Withdrawn - After Issue
- 2018-03-15 BR BR112019018863A patent/BR112019018863A8/pt not_active Application Discontinuation
- 2018-03-15 JP JP2019550622A patent/JP7037577B2/ja not_active Expired - Fee Related
- 2018-03-15 MX MX2019010972A patent/MX2019010972A/es unknown
- 2018-03-15 SG SG11201908527S patent/SG11201908527SA/en unknown
- 2018-03-15 EA EA201992131A patent/EA201992131A1/ru unknown
- 2018-03-15 CN CN201880026621.3A patent/CN110582299A/zh active Pending
-
2019
- 2019-09-10 IL IL26925019A patent/IL269250A/en unknown
- 2019-09-13 US US16/571,013 patent/US11034748B2/en active Active
-
2020
- 2020-12-22 US US17/131,688 patent/US20210355189A1/en not_active Abandoned
-
2021
- 2021-03-12 JP JP2021039957A patent/JP2021090462A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| AU2014407539B2 (en) | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation | |
| JP2026035690A (ja) | 癌を標的とするキメラ抗原受容体 | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| JP2017523784A5 (enExample) | ||
| Shevtsov et al. | Immunological and translational aspects of NK cell-based antitumor immunotherapies | |
| JP2017531687A5 (enExample) | ||
| JP6578604B2 (ja) | 固形がんの治療剤 | |
| AU2016321256A1 (en) | NY-ESO-1 specific TCRs and methods of use thereof | |
| JP2020533962A5 (enExample) | ||
| JP2022527267A5 (enExample) | ||
| CN114616337A (zh) | 嵌合CD3融合蛋白与基于anti-CD3的双特异性T细胞激活元件的联合表达 | |
| JP2021512637A5 (enExample) | ||
| JP2024519335A (ja) | がん免疫療法のための投薬レジメン | |
| JP2023548974A (ja) | Ｔ細胞抗原カプラを含む細胞及びその使用 | |
| CA3215830A1 (en) | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies | |
| JP2021525068A5 (enExample) | ||
| WO2021027785A1 (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| Heiblig et al. | Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors | |
| Zhao et al. | Current status and future perspective of natural killer cell therapy for cancer | |
| Handgretinger et al. | Emerging role of immunotherapy for childhood cancers | |
| JP2022547809A5 (enExample) | ||
| Smits et al. | Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer | |
| Kebriaei et al. | CARs: driving T-cell specificity to enhance anti-tumor immunity | |
| Hazboun | Adoptive cellular immunotherapy for solid tumors |